Ligelizumab

From WikiMD's Wellnesspedia

Ligelizumab is a monoclonal antibody designed for the treatment of chronic spontaneous urticaria (CSU). It is developed by Novartis, a Swiss multinational pharmaceutical company. Ligelizumab works by targeting and neutralizing immunoglobulin E (IgE), a type of antibody that plays a key role in allergic reactions.

Mechanism of Action[edit | edit source]

Ligelizumab is a monoclonal antibody that binds to IgE, preventing it from attaching to mast cells and basophils. This inhibits the release of inflammatory mediators like histamine, which are responsible for the symptoms of CSU.

Clinical Trials[edit | edit source]

Ligelizumab has undergone several clinical trials to evaluate its safety and efficacy. In a Phase IIb study, ligelizumab demonstrated superior efficacy compared to omalizumab, another IgE inhibitor, in patients with CSU who were unresponsive to antihistamines.

Approval[edit | edit source]

As of 2021, ligelizumab is not yet approved by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). However, it is under review by these regulatory bodies.

See Also[edit | edit source]


Ligelizumab Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD